Dr. Andreas Markis 🇬🇧

Medical undergraduate training at Oxford University (Preclinical) and Sheffield
University Medical School (Clinical). Trained in Clinical Oncology at Weston Park
Hospital, Sheffield and the Royal Marsden Hospital, London. Appointed Consultant
Clinical Oncology at the Mount Vernon Cancer Centre, in 1997, and Honorary
Professor at the University of Warwick in 2022.
Specializes in the treatment of breast cancer and has published over 140 papers
to breast cancer research. He is co-Chief Investigator of the OPTIMA Trial which is
investigating whether adjuvant chemotherapy can be avoided in women with highrisk
early breast cancer. He is a member of the Trial Management Groups of many
and international breast cancer trials.
He is a member of the Executive Committee of the UK Breast Cancer Group, and
co-Chair between 2012-22. He is Chairman of the UK Inter-disciplinary Breast
He has served as a clinical adviser to NICE and has been a member of the Scientific
Committee of the Breast Cancer Campaign and the NCRI Breast Cancer Group.
He is a Trustee of the following breast cancer charities: Breast Cancer Now, Marie
Curie Research Trust, Cridlan Trust and Le Cure

15 : 55 – 16 : 25

23 June | 2023 Day 1

Satellite symposium (Lilly) Topic: Updates on CDK4/6 in the Management of EBC

Chair Person : Dr. Taleb Bohlaiaqh
Speaker : Andreas Markis (UK)